Related Experiment Video
Updated: May 18, 2026

A Treatment Package without Escape Extinction to Address Food Selectivity
Published on: August 21, 2015
Insights
The TREAT Registry found that long-term infliximab treatment for Crohn's disease did not increase mortality risk. However, infliximab, corticosteroids, and narcotics were linked to a higher risk of serious infections in patients.
Area of Science:
- Gastroenterology and Hepatology
- Immunology
- Clinical Therapeutics
Background:
- The TREAT Registry provides a 5-year follow-up on Crohn's disease patients in North America, evaluating outcomes with and without infliximab treatment.
- This registry tracked over 6,000 patients, focusing on risks of mortality and serious infections to assess long-term safety profiles.
Discussion:
- Mortality rates were comparable between patients treated with infliximab and those receiving other therapies, aligning with earlier 2-year follow-up data.
- Infliximab, corticosteroids, and narcotic use were identified as factors associated with an increased risk of serious infections.
Key Insights:
- Long-term infliximab therapy in Crohn's disease patients shows similar mortality risks compared to alternative treatments.
- A significant finding is the association of infliximab, corticosteroids, and narcotics with elevated risks of serious infections.
Outlook:
- Further analysis of the TREAT Registry data may elucidate specific risk factors and inform safer treatment strategies for Crohn's disease.
- Comparative studies with other inflammatory bowel disease and rheumatoid arthritis cohorts could provide broader insights into biologic and corticosteroid safety profiles.
Abstract:
The TREAT Registry is an updated submission of the 5-year follow-up of Crohn's disease patients from community and academic centers in North America treated with or without infliximab. Over 6,000 patients were followed for risks of mortality and serious infections. Similar to data presented after nearly 2 years of follow-up, mortality was similar for infliximab- and other-treatment-only patients. Infliximab, corticosteroids and narcotics were associated with increased risks of serious infections. Data presented is similar from data reported for controlled trials and observational series in patients with inflammatory bowel disease and rheumatoid arthritis.
More Related Videos
Related Concept Videos
Pharmaceutical Poisoning: Treatment Strategies
Treatment Resistent Cancers
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
The Placebo Effect
Treatment Resistant Cancers
Alzheimer's Disease: Treatment

